IVERIC bio, Inc. Common Stock
ISEE
ISEE was delisted on the 10th of July, 2023.
68 hedge funds and large institutions have $270M invested in IVERIC bio, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 9 increasing their positions, 16 reducing their positions, and 11 closing their positions.
1,456% more capital invested
Capital invested by funds: $17.3M → $270M (+$252M)
864% more call options, than puts
Call options by funds: $3.64M | Put options by funds: $378K
500% more funds holding in top 10
Funds holding in top 10: 1 → 6 (+5)
182% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 11
42% more funds holding
Funds holding: 48 → 68 (+20)
44% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$12.2M |
| 2 |
VMI
VHCP Management III
New York
|
+$6.07M |
| 3 |
VMI
VHCP Management II
New York
|
+$3.59M |
| 4 |
DM
Deerfield Management
New York
|
+$3.57M |
| 5 |
O
OrbiMed
New York
|
+$3.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.95M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.25M |
| 3 |
TA
Tamarack Advisers
Carlsbad,
California
|
-$1.25M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.25M |
| 5 |
Renaissance Technologies
New York
|
-$493K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
JP Morgan Chase
New York
| – | -$1K | -968 | Closed |
|
77
Barclays
London,
United Kingdom
| – | +$4 | +1 | New |
|
ISEE Hedge Fund Activity: Q4 2019 in Review
68 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio, Inc. Common Stock (ISEE) for Q4 2019, worth a combined $270M — up 1,456% from $17.3M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new ISEE positions and 11 closed out — a net gain of 20 holders — while 9 added to existing stakes and 16 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $12.2M. The largest seller was Stonepine Capital Management, cutting an estimated $2.95M.
- 68 institutional investors held IVERIC bio, Inc. Common Stock (ISEE) as of Q4 2019, up from 48 in Q3 2019.
- Funds reported $270M of IVERIC bio, Inc. Common Stock stock for Q4 2019, up 1,456% quarter-over-quarter.
- 31 funds opened new IVERIC bio, Inc. Common Stock positions in Q4 2019 and 11 closed out, a net change of +20 holders.
- The largest IVERIC bio, Inc. Common Stock buyer in Q4 2019 was Consonance Capital Management, an estimated $12.2M added.
- The largest IVERIC bio, Inc. Common Stock seller in Q4 2019 was Stonepine Capital Management, an estimated $2.95M sold.
Based on aggregated 13F filings for Q4 2019.